A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1

This study is ongoing, but not recruiting participants.

First Received: April 5, 2002 Last Updated: February 8, 2007 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00033124

Purpose

The purpose of this study is to examine behavioral treatment for methamphetamine dependence.

Condition	Intervention	Phase
Substance-Related Disorders	Behavioral: Behavior Therapy	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Behavioral Trial for the Treatment of Methamphetamine Dependence

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine

Drug Information available for: Methamphetamine hydrochloride Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Withdrawal symptoms
New Use algorithm

Estimated Enrollment:	50
Study Start Date:	July 2001
Estimated Study Completion Date:	June 2002

Detailed Description:

To characterize meth. withdrawal symptoms using a multidimensional withdrawal questionnaire; to field test and investigate the effect of using an algorithm developed for discriminating between new use and residual carry-over of meth metabolites in urine and to evaluate the treatment response of meth. users to participation in the thrice weekly psychosocial protocol to be used as a "platform" in future pharmacotherapy trials.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or Female at least 18 yrs of age; DSM-4 diagnosis of methamphetamine (METH) dependence; be willing to comply with study procedures; verbalize understanding of consent and provide written consent and willingness to complete study procedures; be seeking treatment for METH dependence.

Exclusion Criteria:

Additional criteria available during screening at the site.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033124

Locations

United States, California
Matrix Institute on Addictions
Costa Mesa, California, United States, 92627
South Bay Treatment Center
Chula Vista, California, United States, 91911
United States, Hawaii
John A. Burns School of Medicine
Honolulu, Hawaii, United States, 96813
United States, Iowa
Powell Chemical Dependency Center
Des Moines, Iowa, United States, 50316
United States, Missouri
Comprehensive Mental Health Services, Inc
Independence, Missouri, United States, 64052

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Richard Rawson, Ph.D.

National Institute on Drug Abuse (NIDA)

More Information

No publications provided

Study ID Numbers:	NIDA-CTO-0009-1
Study First Received:	April 5, 2002
Last Updated:	February 8, 2007
ClinicalTrials.gov Identifier:	NCT00033124 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Sympathomimetics
Physiological Effects of Drugs
Disorders of Environmental Origin
Central Nervous System Stimulants

Pharmacologic Actions
Methamphetamine
Mental Disorders
Autonomic Agents
Therapeutic Uses
Substance-Related Disorders
Amphetamine
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 09, 2009